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Abstract In this study we report the activation of c-Jun N-
terminal kinase (JNK) in human K562 erythroleukemia cells
undergoing hemin-mediated erythroid differentiation, which
occurs concomitantly with activation of heat shock factor 2
(HSF2) and leads to a simultaneous in vivo phosphorylation of
c-Jun. The activation of JNK occurs through activation of
mitogen-activated protein kinase kinase (MKK) 4 and not by
activation of MKK7 or inhibition of JNK-directed phosphatases.
We have previously shown that overexpression of the HSF2-L
isoform inhibits the activation of HSF2 upon hemin-induced
erythroid differentiation. Here we demonstrate that HSF2-L
overexpression blocks the hemin-induced activation of the
MKK4-JNK pathway, suggesting an erythroid lineage-specific
JNK activation likely to be regulated by HSF2. ß 2001 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
The JNK/SAPK pathway is a member of the mitogen-acti-
vated protein kinase (MAPK) pathways and is known to be
activated by pro-in£ammatory cytokines and by physical and
chemical stresses, as well as by apoptotic signals [1]. Three
genes, c-Jun N-terminal kinases (JNKs) 1, 2 and 3, encoding
10 JNK isoforms have been cloned. Of these, JNKs 1 and 2
are abundantly expressed, whereas JNK3 is more highly ex-
pressed in neural tissues [2]. Activation of JNKs can occur by
activation of the MAPK kinases MKK4/SEK1 or MKK7 [1],
or alternatively by inhibition of JNK phosphatases [3].
Although more information on the role of JNK in apoptosis
and embryonic morphogenesis is accumulating, the role of
JNK signaling during di¡erentiation-related processes has re-
mained elusive [4].
K562 human erythroleukemia cells have been widely used
as a cellular model for hematopoietic di¡erentiation, as they
can be stimulated to di¡erentiate along megakaryocytic, ery-
throid, and to a lesser extent, monocytic lineages [5,6]. In
response to hemin, K562 cells start to di¡erentiate along the
erythroid lineage, as characterized by elevated expression of
embryonic and fetal globins [7]. While MAPK/ERK signaling
has been shown to be important for the megakaryocytic dif-
ferentiation [8], relatively little is known about signaling
events during erythroid di¡erentiation.
HSF2 is a member of the heat shock transcription factor
family known to regulate transcription of genes encoding heat
shock proteins (Hsps) [9]. In contrast to the classical stress-
responsive heat shock factor, HSF1, abundant expression and
activation of HSF2 have been associated with development-
and di¡erentiation-related processes [10^16]. Curiously, no
spatial or temporal correlation between activation of HSF2
and expression of Hsps has been shown during mouse em-
bryogenesis, heart development or rat spermatogenesis
[13,14,16], which has raised the possibility that HSF2 may
have target genes distinct from those of HSF1 [17,18]. HSF2
exists as two alternatively spliced isoforms HSF2-K and
HSF2-L, displaying tissue-speci¢c expression and distinct
transcriptional activities [19]. We have earlier demonstrated
that HSF2 expression and acquisition of HSF2 DNA binding
activity are strictly speci¢c for the erythroid characteristics of
K562 cells, since HSF2 is rapidly downregulated during mega-
karyocytic di¡erentiation [15]. This indicates that HSF2
could have a role as a lineage-speci¢c regulator of erythroid
di¡erentiation. Here we show that JNK is strongly activated
concomitantly with the activation of HSF2 during hemin-in-
duced erythroid di¡erentiation of K562 cells. The JNK acti-
vation is exclusively mediated by MKK4 and not by MKK7
or phosphatase inhibition, and it leads to a simultaneous in
vivo phosphorylation of c-Jun. Interestingly, overexpression
of the HSF2-L isoform, which has been previously shown to
abolish the erythroid lineage-speci¢c activation of HSF2 and
suppress the erythroid di¡erentiation [20], also prevents the
observed activation of JNK, suggesting a novel, HSF2-medi-
ated mechanism of JNK regulation during erythroid di¡er-
entiation of K562 cells.
2. Materials and methods
2.1. Cell culture
Human K562 erythroleukemia cells were cultured in a humidi¢ed
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5% CO2 atmosphere at 37‡C in RPMI 1640 supplemented with 10%
fetal calf serum (FCS) and antibiotics (penicillin and streptomycin).
K562 cells stably overexpressing HSF2-K and HSF2-L isoforms
(2K-C7 and 2L-D5, respectively) [19] were maintained in RPMI
1640 containing G418 (500 Wg/ml; Gibco BRL). For experimental
treatments, the HSF2-K- and HSF2-L-overexpressing cells were plated
in RPMI 1640 without G418. Hemin (Aldrich) was added to a ¢nal
concentration of 40 WM, anisomycin (Calbiochem) to 5.0 Wg/ml, and
TPA (Sigma) to 10 nM. For osmotic shock treatments, cells were
incubated for 10 min in medium containing 0.5 M NaCl. Heat shock
was performed at 42‡C in a water bath. For UV irradiation, cells were
exposed to a 15 W UV light for 5 min.
2.2. Plasmid constructs and transfection
The plasmid for the bacterial expression of JNK1 was a gift from
Dr. Roger Davis (University of Massachusetts Medical School, Wor-
cester, MA, USA) and the plasmid for expression of GST-c-Jun was a
gift from Dr. James Woodgett (Ontario Cancer Institute, Toronto,
ON, Canada). For measurement of kinase activities, cells were trans-
fected with wild-type GST-tagged MKK4/SEK1 (pEBG-SEK1) [21]
or with wild-type FLAG-tagged MKK7 (a kind gift from Dr. James
Woodgett). HSF2-K-Myc plasmid is described in detail elsewhere
(Alastalo et al., in preparation). For transfections 5U106 cells were
suspended in 0.4 ml OptiMEM (Gibco BRL) and 10^50 Wg DNA was
added. The cells were then subjected to a single electric pulse (975 WF,
200 V) in 0.4 cm gap electroporation cuvettes (BTX) followed by
dilution to 5U105 cells/ml in RPMI 1640 containing 10% FCS and
antibiotics.
2.3. SDS^PAGE and Western blotting
3U106 cells were lysed in Laemmli sample bu¡er and sonicated to
reduce sample viscosity. 5 Wl of samples were separated on a 10% SDS
polyacrylamide gel and transferred to nitrocellulose membrane (Pro-
tran nitrocellulose; Schleicher and Schuell) using a semi-dry transfer
apparatus (Bio-Rad). Western blotting was performed using antibod-
ies against phospho-JNK (Promega), c-Jun (New England Biolabs),
JNK1(FL) (Santa Cruz), HSC70 (StressGen), and HSF2 (a kind gift
from Dr. Richard I. Morimoto, Northwestern University, Evanston,
IL, USA). Horseradish peroxidase-conjugated secondary antibodies
were purchased from Promega and Zymed. The blots were developed
using the enhanced chemiluminescence method (ECL; Amersham).
2.4. Gel mobility shift assay
A gel mobility shift analysis of protein^DNA complexes was per-
formed as described previously [22]. Brie£y, whole cell extracts (12 Wg
protein) were incubated with a 32P-labeled oligonucleotide represent-
ing the proximal HSE of the human hsp70 promoter. The protein^
DNA complexes were resolved on a 4% non-denaturing polyacryl-
amide gel.
2.5. In vitro immunocomplex kinase assay for JNK
Cells for JNK assays were lysed in lysis bu¡er (1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA, 1 mM
sodium orthovanadate, 20 mM sodium £uoride, 1 mM dithiothreitol
(DTT) in phosphate-bu¡ered saline, pH 7.4). Transfected cells were
harvested 48 h post-transfection. Insoluble material was removed by
centrifugation, and the cell lysate was incubated with an antibody
speci¢c for JNKs (Santa Cruz), together with protein A Sepharose
(Sigma) at 4‡C overnight. The beads were washed three times with the
lysis bu¡er, three times with LiCl bu¡er (500 mM LiCl, 100 mM Tris,
pH 7.6, 0.1% Triton X-100, 1 mM DTT in H2O), and three times with
JNK kinase assay bu¡er (20 mM MOPS, pH 7.2, 2 mM EGTA,
10 mM MgCl2, 0.1% Triton X-100, 1 mM DTT in H2O). Immuno-
precipitates were mixed with 5 Wg of GST-c-Jun, 25 Wmol ATP, 50 mM
MgCl2 and 2.5 WCi of [Q-32P]ATP in 40 Wl kinase bu¡er followed by a
30 min incubation at 37‡C. The reactions were terminated by boiling
in Laemmli sample bu¡er. Samples were resolved on 10% SDS^PAGE
and autoradiographed.
2.6. Two-step immunocomplex kinase assay for MKK4 and MKK7
K562 cells were transfected with tagged wild-type MKK4 or MKK7
kinase constructs and the assay was done 40 h after the transfection to
measure kinase activity. The cells were lysed in lysis bu¡er (20 mM
Tris pH 7.4, 10% glycerol, 1% Triton X-100, 137 mM NaCl, 25 mM
L-glycerophosphate, 2 mM EDTA, 1 mM Na3VO4, 50 mM NaF).
Cleared cell lysate was incubated overnight with 40 Wl of GSH-Se-
pharose beads (Sigma) for MKK4 or 2.5 Wg M2 anti-FLAG antibody
(Sigma) and 40 Wl of protein G Sepharose beads (Amersham) for
MKK7. The beads were washed three times with lysis bu¡er, three
times with LiCl bu¡er, and three times with kinase assay bu¡er
(20 mM MOPS, pH 7.2, 2 mM EGTA, 1 mM DTT, 0.1% Triton
X-100, 10 mM MgCl2). Samples were then incubated 15 min at
30‡C in 30 Wl of reaction mix containing 50 WM ATP, 25 mM MgCl2,
25 mM L-glycerophosphate, 0.1 mM Na3VO4, and 0.5 Wg JNK1 in
kinase assay bu¡er, after which 2 Wg GST-c-Jun and 5 WCi of
[Q-32P]ATP were added, and the reaction was further incubated for
30 min at 30‡C. The reaction was terminated by addition of Laemmli
sample bu¡er followed by boiling. Samples were resolved on 12.5%
SDS^PAGE and autoradiographed.
2.7. JNK phosphatase assay
The assay was done as previously described [3]. Brie£y, JNK was
activated with various treatments and further phosphorylation of
JNK was inhibited by addition of 4 WM staurosporine (Sigma). The
dephosphorylation kinetics of JNK was detected by Western blotting
using a phospho-JNK-speci¢c antibody.
Fig. 1. Activation of JNK follows the HSF2 DNA binding activity during hemin-induced erythroid di¡erentiation of K562 cells. A: An in vitro
immunocomplex kinase assay for JNK was performed with extracts from untreated (C) K562 cells, and from K562 cells treated for the indi-
cated time periods with hemin (40 WM) or with UV irradiation. B: Whole cell extracts (12 Wg) from control (C) K562 cells, and from K562
cells treated for the indicated time periods with hemin (40 WM) or heat shock (HS; 42‡C) were analyzed by gel mobility shift assay. HSF-HSE
indicates the speci¢c inducible HSF^HSE complex, CHBA indicates the constitutive HSE binding activity, NS denotes the non-speci¢c protein^
DNA interactions.
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3. Results and discussion
To study JNK activities during erythroid di¡erentiation of
K562 cells, hemin-treated cells were analyzed by an in vitro
JNK activity assay using bacterially expressed GST-c-Jun as a
substrate (Fig. 1A). The JNK activity increased markedly
after 11 h of hemin treatment (V7-fold), and by 24 h, the
JNK activity was s 15-fold compared to the control levels.
Immunoblot analysis of total JNK protein levels showed no
changes during hemin treatment (data not shown). The ki-
netics of HSF2 DNA binding activity was determined using
gel mobility shift assay. As shown in Fig. 1B, after 10 h treat-
ment with hemin a prominent and sustained HSF2 DNA
binding activity was evident, which is in agreement with our
earlier results [10,15,20]. The activation kinetics varied be-
tween separate experiments, but in all experiments HSF2
DNA binding activity was observed 1^2 h before the JNK
activation.
The concomitant activation of HSF2 and JNK prompted us
to examine hemin-induced JNK activity in 2K-C7 and 2L-D5
cell lines stably overexpressing HSF2-K and HSF2-L, respec-
tively (Fig. 2A), since in previous studies we have shown that
the hemin-induced HSF2 activation is repressed in HSF2-L-
overexpressing cells (2L-D5) [20]. As compared to the parental
K562 cells, the hemin-induced activation of both HSF2 (Fig.
2B, left panel) and JNK was completely abolished in 2L-D5
cells, whereas UV irradiation led to a clear induction of JNK
activity (Fig. 2C). In contrast to the 2L-D5 cells, in the HSF2-
K-overexpressing cell line 2K-C7, which shows a normal acti-
vation of HSF2 (Fig. 2B, middle panel) [20], JNK was equally
well activated by hemin as in the parental K562 cells (Fig.
2D). To demonstrate that the absence of hemin-induced JNK
activity in 2L-D5 was not the result of decreased JNK levels,
Western blot analysis for JNK was carried out in parallel
(Fig. 2E). This con¢rms that speci¢c JNK activity is not ele-
vated in 2L-D5 cells. We also tested whether the inhibitory
e¡ect of HSF2-L could be a¡ected by overexpression of
HSF2-K. However, the hemin-induced JNK activation could
not be restored by increasing the amount of HSF2-K in 2L-D5
cells (Fig. 2F).
To study the upstream regulatory pathways leading to JNK
activation upon hemin-mediated erythroid di¡erentiation of
K562 cells, we analyzed the activity of transfected upstream
JNK kinases, MKK4 and MKK7, by employing in vitro two-
step immunocomplex kinase assays. As shown in Fig. 3A,
MKK4 was strongly (s 5-fold) activated by hemin with sim-
ilar kinetics as JNK, whereas mock transfectants displayed no
kinase activity. In contrast to MKK4, MKK7 was not acti-
vated during hemin treatment, whereas hyperosmotic shock
with 0.5 M NaCl induced a strong activation of MKK7
C
Fig. 2. Inhibition of JNK activation in K562 cells overexpressing
the HSF2-L isoform. A: Western blot analysis of HSF2 was per-
formed from lysates of K562, 2K-C7 and 2L-D5 cells. Hsc70 was
blotted to demonstrate equal loading. HSF2-K/L : endogenous HSF2
isoforms; mHSF2-K/L : stably transfected mouse HSF2-K/L. B: Gel
mobility shift assays were performed as described in Fig. 1 for cell
lysates from 2L-D5 (left panel) and 2K-C7 (right panel) cells. C: An
in vitro immunocomplex kinase assay for JNK was performed from
untreated (C), hemin-treated (40 WM) or UV-treated K562 cells sta-
bly overexpressing the mouse HSF2-L isoform (2L-D5). D: Analysis
of JNK activities in control (C) and hemin-treated (40 WM) K562
cells overexpressing the HSF2-K isoform (2K-C7) was performed as
in B. E: Western blot analysis of phosphorylated JNK was per-
formed from lysates of untreated (C) or hemin-treated (He; 40 WM,
16 h) K562, 2K-C7 and 2L-D5 cells. Total JNK levels are shown by
JNK immunoblot. F: 2L-D5 cells were mock-transfected or trans-
fected with HSF2-K-Myc and treated as indicated. Analysis of JNK
activities was done as in C. Western blot analysis of HSF2. HSF2-
K/L : endogenous HSF2 isoforms; mHSF2-L : stably transfected
mouse HSF2-L ; HSF2-K-Myc: transiently transfected human HSF2-
K-Myc; *: unspeci¢c band or a proteolytic product.
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(Fig. 3B). It has been shown by Meriin and co-workers [3]
that certain protein-damaging stresses can activate JNK via
another regulatory mechanism, namely phosphatase inhibi-
tion. To study the rate of JNK dephosphorylation upon hem-
in treatment, staurosporine, a non-speci¢c kinase inhibitor,
was used to block further phosphorylation of JNK. Western
blotting with phospho-JNK-speci¢c antibody revealed a fast
JNK dephosphorylation in hemin-treated K562 cells, which
was comparable to that detected during UV-induced JNK
activation (Fig. 3C, upper panel). Already 5 min treatment
with staurosporine resulted in almost total dephosphorylation
of JNK in cells exposed to either hemin or UV, whereas in
cells exposed to heat shock, JNK remained strongly phos-
phorylated even after 20 min of staurosporine. The same re-
sult was obtained when the rate of JNK dephosphorylation
was detected by in vitro immunocomplex kinase assay (data
not shown).
To study whether the HSF2-L-mediated suppression of
JNK activation acts directly on JNK or further upstream,
the activity of MKK4 was determined in 2L-D5 cells. As
shown in Fig. 3D, no hemin-induced activation could be ob-
served in these cells, although the cells displayed a marked
activation of MKK4 upon stimulation with anisomycin or
UV. These results show that the signaling pathway involving
MKK4 was a¡ected by overexpression of the inhibitory
HSF2-L isoform.
To test whether hemin-induced JNK activation played a
role in the transcriptional regulation of gene expression during
erythroid di¡erentiation of K562 cells, we analyzed the ex-
pression and phosphorylation states of c-Jun by immunoblot-
ting with an antibody detecting total c-Jun levels. The di¡er-
ent phosphorylation states of c-Jun protein could be seen as
several more slowly migrating bands. By 10 h of hemin treat-
ment, the phosphorylated forms of c-Jun could be readily
detected and their intensities were further increased by 24 h
of hemin treatment (Fig. 4A, upper panel). The amounts of
Hsc70, a constitutively expressed member of the 70 kDa Hsp
family, are shown as a control for equal loading of samples
(Fig. 4A, lower panel). The phosphorylation of c-Jun was re-
pressed in HSF2-L overexpressing K562 cells, consistent with
the absence of JNK activation (Fig. 4B).
The present study shows a signi¢cant activation of the JNK
pathway during the erythroid di¡erentiation process of K562
erythroleukemia cells. Previously hematopoietic cytokines,
such as erythropoietin (Epo), regulating erythroid di¡erentia-
tion have been shown to activate JNKs in Epo-dependent
mouse cell lines [23,24]. In these experiments, the mode of
JNK activation appears to be somewhat di¡erent from the
activation observed by us, because the activation induced by
Epo was rapid and transient, which indicates that di¡erent
mechanisms may be employed by distinct modes of di¡eren-
tiation. Also the upstream regulation appears to be di¡erent,
since Epo-induced JNK activation is not mediated by MKK4
[23].
Activation of JNK is usually a fast and direct signaling
Fig. 3. Hemin-induced JNK activation is mediated via MKK4 and
overexpression of HSF2-L blocks the activation of MKK4. A: A
two-step in vitro immunocomplex kinase assay for MKK4 was per-
formed with extracts of untreated K562 cells (C), K562 cells treated
with hemin (40 WM), UV (10P) or anisomycin (ANI; 5 Wg/ml) 40 h
after transfection of a plasmid expressing GST-tagged wild-type
MKK4 or mock transfection. B: A two-step in vitro immunocom-
plex kinase assay for MKK7 was performed as in A after transfec-
tion of a FLAG-tagged wild-type MKK7. Osmotic shock (NaCl,
0.5 M, 10 min) was used as a positive control. M indicates mock-
transfected cells. C: Western blot analysis of the phosphorylation
states of JNK. For the analysis of the JNK dephosphorylation ki-
netics, JNK was activated with UV (10 min), hemin (40 WM, 24 h),
and heat shock (HS; 45‡C, 20 min), and further phosphorylation
was blocked with staurosporine (S; 4 WM). Western blot analysis of
the total JNK levels is shown in the lower panel. D: An identical
procedure to that in A was performed in 2L-D5 cells stably overex-
pressing HSF2-L.
Fig. 4. c-Jun is a putative target for hemin-induced JNK activation.
A: Western blot analysis showing the expression levels and phos-
phorylation states of c-Jun. Cell lysates from untreated K562 cells
(C), and K562 cells treated with hemin (40 WM) or anisomycin
(Ani; 5.0 Wg/ml) were subjected to SDS^PAGE and immunoblot
analysis using an antibody detecting the total c-Jun protein. The dif-
ferent phosphorylation states of c-Jun can be seen as more slowly
migrating bands on the gel (P-c-Jun). Hsc70 protein levels from the
same samples are shown in the lower panel as a loading control.
B: Western blot analysis showing the expression levels and phos-
phorylation states of c-Jun in cell lysates of untreated (C), hemin-
treated (He; 40 WM) and anisomycin-treated (Ani; 5.0 Wg/ml) 2L-D5
cells. Hsc70 is shown as a loading control.
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response to stimuli associated with cellular stresses or expo-
sure to pro-in£ammatory cytokines [25,26]. In comparison to
stress- or cytokine-mediated activation, the hemin-induced
JNK activation is a very slow process with su⁄ciently delayed
kinetics to allow for synthesis of new proteins, whose expres-
sion could be regulated by HSF2. Although we cannot dissect
whether the inhibitory e¡ect of HSF2-L on JNK signaling is
mediated directly by preventing HSF2 activity, or indirectly
by suppressing erythroid di¡erentiation, our study suggests
that the activation of HSF2 could be a crucial step leading
to JNK activation during this di¡erentiation process.
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